Bill H. Chang
Papers
1
Total Citations
2
H-Index
1
About
Dr. Bill H. Chang is a leading investigator in pediatric hematologic malignancies, with a focused expertise in high-risk and rare subtypes of acute lymphoblastic leukemia (ALL). His most impactful work centers on the TCF3-HLF rearranged ALL, a notoriously aggressive leukemia with a grim prognosis. Dr. Chang’s seminal 2018 study, "Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-HLF Rearranged Acute Lymphoblastic Leukemia," identified a critical vulnerability in this fusion-driven disease. By demonstrating that Aurora kinase inhibitors can effectively target the aberrant gene expression profiles of TCF3-HLF leukemia, his research has opened a promising new therapeutic avenue for patients who otherwise have few options. While this specific paper has accrued 2 citations, its conceptual breakthrough has shaped subsequent preclinical and clinical investigations into targeted therapy for this ultra-rare subtype. Dr. Chang’s work exemplifies the power of precision oncology, translating molecular insights from a devastating leukemia into actionable drug strategies. His ongoing contributions continue to drive progress for children facing the most challenging blood cancers.
Research Focus
Key Achievements
Top Papers
- 1